Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma via the PTEN/AKT Signalling Pathway

Xiao-ming Zhang1,2, Zeng-li Liu1, Bo Qiu3, Yun-fei XU1, Chang Pan3, Zong-li Zhang1

1. Department of general surgery, Qilu Hospital of Shandong University, No. 107, Wenhua Xi Road, Jinan, 250012, China.
2. Department of general surgery, Linyi People’s Hospital, Linyi, 276000, China.
3. Department of general surgery, Qilu Hospital of Shandong University (Qingdao), 266035, China.
4. Department of emergency, Qilu Hospital of Shandong University, No. 107, Wenhua Xi Road, Jinan, 250012, China.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Abstract

Aims: Hilar cholangiocarcinoma (HCCA) is a tumour with high malignancy, low surgical resection potential, and a poor prognosis. Ecotropic Viral Integration site 1 (EVI1) is a transcriptional regulator that has been proven to be associated with tumourigenesis and progression in many human solid tumours. However, the expression of EVI1 and its role in HCCA progression remain unclear. The aim of this study was to clarify the association between EVI1 expression and clinical outcomes in patients with HCCA.

Methods: The expression of EVI1 in HCCA tissue samples and cell lines was examined by quantitative real-time PCR (qRT-PCR), Western blotting, and immunohistochemistry (IHC). Kaplan-Meier analysis was used for survival analysis. A log-rank test was performed for univariate analysis of survival, and a Cox regression model was utilized for multivariate analysis of survival. Cell proliferation was measured by cell counting kit-8 (CCK-8), colony formation, and 5-ethynyl-2’-deoxyuridine (EdU) assays. The cell cycle was evaluated by flow cytometry. Cell apoptosis was detected by flow cytometry and a terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labelling (TUNEL) assay. In vivo tumour growth was observed for xenografts in nude mice.

Results: EVI1 expression was upregulated in HCCA tissue samples and correlated with a poor prognosis. In clinical specimens, the expression of EVI1 correlated with tumour histological grade and tumour size. Knocking down EVI1 expression reduced HCCA cell proliferation, blocked cell cycle progression, and promoted apoptosis in vitro and in vivo. Furthermore, we found that EVI1 could regulate the AKT signalling pathway by regulating PTEN levels in HCCA.

Conclusion: Our data revealed that EVI1 played important roles in HCCA tumourigenesis and development. Our findings suggest that EVI1 may be a potentially useful therapeutic target in HCCA.

Key words: Hilar cholangiocarcinoma, EVI1, Cell proliferation, PTEN

Introduction

Cholangiocarcinoma (CCA) originates in the epithelial cells of the bile duct wall, and its incidence has increased significantly in the past several decades[1]. Hilar cholangiocarcinoma (HCCA) is the
most common type of CCA[2], accounting for 58-66% of Chinese CCA cases[3]. Surgical resection is still the only curative treatment approach, but it can be applied only to patients with early-stage HCCA[4]. Unfortunately, most patients with HCCA are diagnosed at an advanced stage, and tumour resection rates are frustratingly low[5, 6]. Although the combination of cisplatin and gemcitabine is the standard first-line chemotherapy, the efficacy of this treatment regimen is discouraging[3, 7]. Therefore, the identification of new signalling molecules involved in the proliferation and progression of HCCA cells is critical for the development of new drugs to treat this disease.

Ectropic viral integration site 1 (EVI1), which forms a fusion gene with MDS1 named MECOM, is a nuclear transcription factor that is indispensable for normal development and oncogenesis[8]. EVI1 overexpression and activation have been proven to result in genomic instability and clonal evolution in myelodysplastic syndrome (MDS) and eventually lead to acute myeloid leukaemia (AML)[9, 10]. In addition to malignancies of haematopoietic origin, some solid tumours, such as melanoma, prostate cancer, breast cancer, and ovarian cancer, also exhibit EVI1 overexpression, and the involvement of EVI1 in the occurrence and/or progression[11, 12] of these tumours has been shown. A recent study showed that the expression of EVI1 was upregulated in over 50% of intrahepatic cholangiocarcinomas (ICCs), and patients with EVI1-high ICC showed worse overall survival than patients with EVI1-low ICC[13]. However, the relevance of EVI1 and HCCA is still elusive. In the present study, we explored the expression and biological function of EVI1 in HCCA.

Although accumulating studies have shown the involvement of EVI1 in tumour progression, the mechanism by which EVI1 promotes tumourigenesis and progression has not been fully elucidated. A recent study demonstrated that EVI1 downregulated Phosphatase and tensin homologue (PTEN) expression and activated the AKT signalling pathway in leukaemia cells, thereby causing malignant cell proliferation[14]. Therefore, EVI1-mediated tumour progression may be attributed to the downregulation of PTEN expression. PTEN is an important tumour suppressor gene that negatively regulates the PI3K/PKB/Akt signalling pathway. Although a decrease in PTEN expression is observed in most solid tumours, genetic mutations in PTEN are quite rare in most cancer types, except glioblastoma multiforme and endometrial cancer[15]. Therefore, the most likely reason for the loss of PTEN activity or protein expression in HCCA or other types of cancer might be downregulation by transcriptional regulation. In our study, the influence of EVI1 on the expression of PTEN in HCCA was evaluated.

Here, we showed that overexpression of EVI1 was associated with poor survival in patients with HCCA. Downregulation of EVI1 expression inhibited proliferation and promoted apoptosis in HCCA cells. This repression may be caused by downregulating PTEN expression and thus inactivating the AKT pathway. EVI1 may be a key potential new target for the treatment of HCCA.

Materials and Methods

Tissue samples

Paired HCCA tumour tissue samples and adjacent normal bile duct tissue samples were obtained from 30 consecutive patients who underwent therapeutic resection of HCCA at Qilu Hospital of Shandong University during 2017-2018. The study obtained informed consent from all participants, who were confirmed to have HCCA by pathology. All the specimens were collected in accordance with procedures authorized by the ethics committee of Qilu Hospital of Shandong University and stored at -80°C until use.

Human HCCA tissue microarray

A human HCCA tissue microarray (TMA) containing 114 samples of HCCA tissue was immunohistochemically stained for EVI1 and PTEN and analysed for correlations between EVI1 and clinicopathological features. Clinical characteristics of all patients contained in the TMA were collected and are shown in Table 1.

Cell lines and culture

QBC939 and RBE cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Other cell lines, including FRH0201 and HCCC9810, and human intrahepatic biliary epithelial cells (HIBEpiC) were preserved in our laboratory. QBC939 cells and HIBEpiC were cultured in DMEM (Gibco, USA) supplemented with 10% foetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin. RBE, FRH0201 and HCCC9810 cells were cultured in RPMI-1640 (Gibco) supplemented with 10% FBS (Gibco) and 1% penicillin/streptomycin. All the cells were maintained at 37°C in a humidified incubator under 5% CO2 conditions.

Stable cell line construction and siRNA interference

EVI1-specific shRNA and noncoding shRNA lentiviral particles were purchased from GeneChem (Shanghai, China). For construction of HCCA with
stably downregulated EVII expression, the EVII-specific shRNA and noncoding shRNA lentiviral particles were transfected into QBC939 cells, and then the cells were selected with 2 μg/mL puromycin for 4 weeks. The cells were transfected with Lipofectamine 2000 (Invitrogen) in Opti-MEM (Gibco) according to the manufacturer’s instructions. The EVII overexpressing plasmid and a PTEN-specific siRNA were purchased from GenePharma (Shanghai, China). The siRNA sequence targeting PTEN was as follows: 5’-GAAGAUAUAUUCUCCAUTTAAUGGAGGA AUUAUCUUCTT-3’.

**RNA extraction and qRT-PCR**

Total RNA was isolated from tissue samples and cells using Trizol reagent (Invitrogen), and 2 μg of total RNA was reverse transcribed to obtain first-strand cDNA using an RNA-PCR kit (Takara) following the manufacturer’s protocols. The resulting cDNA was used for real-time RT-PCR using a SYBR Green PCR Master Mix kit (Applied Biosystems) according to the manufacturer’s instructions. The primers for EVII were: forward, 5’-GATTGCAGAACCAGCTCAAGT-3’ and reverse, 5’-CTATTGGCGCACAATAGTCAG-3’. The primers for PTEN were: forward, 5’-GACAGAGACAAAAAGGGAGTAGTAUAG-3’ and reverse, 5’-CTATTGGCGCACAATAGTCAG-3’. Relative quantification was performed by the 2-ΔΔCt method.

**Western blot analysis**

Cell lysates were prepared by using RIPA lysis buffer (Beyotime, China), and the total protein concentration was determined by using a BCA protein detection kit (Pierce Biotechnology). Target proteins were separated by 8-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene fluoride (PVDF) membranes. After blocking with 5% bovine serum albumin for 1 h, the PVDF membranes were incubated with primary antibodies at 4°C overnight. The following antibodies were used: anti-EVII (album, ab124934); anti-MECOM (ATLAS ANTIBODIES, HPA046537); anti-Lamin B (Beyotime, AF1186); anti-Akt (Cell Signaling Technology, 4691); anti-p-Akt (Cell Signaling Technology, 4060); anti-Cyclin A (Cell Signaling Technology, 4656); anti-p21 (Cell Signaling Technology, 2947); anti-CDK2 (Cell Signaling Technology, 2546); anti-Bcl-2 (Cell Signaling Technology, 4223); anti-Bax (Cell Signaling Technology, 5023); anti-Caspase 3 (Cell Signaling Technology, 9665); and anti-PTEN (Cell Signaling Technology, 9188). After washing with TBST, the membranes were incubated with secondary antibodies for 1 h. Signals were detected with an ECL detection reagent (Beyotime).

**Cell proliferation and colony formation**

For a cell proliferation assay, transfected cells were seeded in 96-well plates at 3×10³ cells per well and incubated at 37°C for 24 h, 48 h, 72 h, 96 h or 120 h. Then, 10 μl of cell counting kit-8 (CCK-8) reagent (Dojindo, Kumamoto, Japan) was added to each well and incubated at 37°C for 1 h. The absorbance value at 450 nm was detected by a microplate reader. For a colony formation assay, 500 cells per well were plated in 6-well plates and incubated in DMEM supplemented with 10% FBS for 14 days. The colonies were fixed with methanol and stained with 0.5% crystal violet. Then, the visible colonies were counted.

**EdU pulse-chase incorporation**

A 5-ethyl-2'-deoxyuridine (EdU) assay was performed to assess cell proliferation by using the Cell-Light EdU DNA Cell Proliferation Kit (RiboBio, China). Transfected cells were seeded in 30-mm Petri dishes and cultivated until they filled the petri dishes. Cell proliferation and colony formation were fixed with methanol and stained with 0.5% crystal violet. Then, the visible colonies were counted.

**Flow cytometric analysis of the cell cycle and apoptosis**

For cell cycle analyses, transfected cells were collected and washed twice with phosphate-buffered saline. Then, the centrifuged cells were fixed in 75% ethanol at 4°C overnight. The cells were centrifuged again, stained using PI/RNase Staining Buffer (BD Bioscience Pharmingen, USA), and then analysed using flow cytometry. Cell apoptosis was detected using the PE Annexin V Apoptosis Detection Kit (BD Bioscience Pharmingen, USA). Cells contained in the supernatant were harvested and centrifuged. The cells were re-suspended in a binding buffer containing PE-Annexin and 7-AAD according to the manufacturer’s instructions. The percentages of apoptotic cells were analysed by flow cytometry.

**TUNEL assays**

A terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labelling (TUNEL) assay was also used to assess cell apoptosis. Transfected cells were seeded in 30-mm petri dishes and cultivated until they filled the petri dishes. Cell fixation, permeabilization and TdT incubation were performed following the manufacturer’s instructions.
for the TUNEL Apoptosis Detection Kit (Alexa Fluor 647) (Yeasen, Shanghai, China).

**In vivo tumourigenicity assays**

QBC939 cells (4×10⁶) transfected with shEVI1 or a negative control (NC) were subcutaneously injected into the right flank of female BALB/c nude mice (6–8 weeks of age). Each group contained 6 mice. Tumour size was measured every 3 days. Tumour volume was determined using the following formula:\[ V = \frac{\text{length} \times \text{width}^2}{2}. \] The mice were sacrificed on the 21st day after injection, and the xenograft tumours were removed and weighed. The Animal Welfare Committee of Shandong University approved all procedures involving animals.

**Immunohistochemical staining**

A two-step approach was used for immunohistochemistry (IHC). After microwave antigen retrieval, anti-EVI1 or anti-PTEN primary antibodies were incubated with microarray and xenograft tissue sections overnight at 4°C. After washing, the tissue sections were incubated with biotinylated goat anti-rabbit antibodies at room temperature for 30 minutes. After DAB staining and haematoxylin counterstaining, the tissue sections were mounted in neutral gum and observed with a bright-field microscope. The staining intensity was evaluated as follows: strongly positive samples (scored as ++++) had dark brown staining in more than 50% of tumour cells, and the staining completely covered the cytoplasm; moderately positive samples (scored as ++) had dark brown staining in 25-50% of tumour cells, whose cytoplasm was blurred; weakly positive samples (scored as +) had less brown staining of the cytoplasm; and "absence" (scored as -) defined samples with no significant staining in tumour cells. Strong and moderate scores were considered positive results. The TMA was scanned by HistoRx PM-2000™ and analysed by AQUAnalysis software.

**Statistics**

Statistical tests were performed by using SPSS 17.0 statistical software packages (IBM, Armonk, NY, USA). Results are expressed as the mean±standard deviation (SD). All experiments were repeated three times, unless otherwise specified. The correlations between EVI1 and clinicopathological characteristics were analysed by the χ² test. The correlation between EVI1 and PTEN was detected by linear correlation analysis. An independent-sample t test was used to compare differences between two groups. One-way ANOVA was used to analyse the differences among three groups. If there were significant differences, multiple comparisons were made between the groups. Univariate and multivariate Cox regression analyses were used to analyse survival data. P-values were considered statistically significant at less than 0.05.

**Results**

**EVI1 expression is upregulated in HCCA tissue and related to a poor prognosis**

To explore the role of EVI1 in HCCA, we detected the expression level of EVI1 in 30 pairs of HCCA tissue and adjacent normal bile duct tissue by quantitative real-time PCR (qRT-PCR) and Western blotting. We found that the mRNA level of EVI1 was significantly higher in the HCCA samples than in the noncancerous matched samples (P=0.0002, Figure 1A). Additionally, we found that EVI1 expression was also upregulated in the HCCA tissue samples compared with the corresponding adjacent normal tissue samples at the protein level (Figure 1B). EVI1 expression was further analysed in an HCCA TMA. We found that EVI1 was overexpressed in the HCCA tissue samples (Figure 1C) and was correlated with poor overall survival (OS) (P= 0.0042, Figure 1D). Together, these results revealed that EVI1 expression was significantly upregulated in HCCA and that overexpression of EVI1 was associated with a poor prognosis.

**Correlations between EVI1 and HCCA clinical parameters**

We analysed the correlations between EVI1 and clinicopathological factors of HCCA. As shown in Table 1, high expression of EVI1 was markedly related to advanced tumour histological grade and increased tumour size (P=0.008 and P=0.023, respectively). EVI1 expression was not associated with age, sex, tumour depth, lymphatic metastasis, or TNM stage (all P> 0.05, Table 1). Then, we assessed the predictive value of EVI1 using the Cox-proportional hazards model (Table 2). Univariate Cox regression analyses of OS demonstrated that histological grade (P=0.039), tumour size (P=0.004), lymphatic metastasis (P=0.011), TNM stage (P=0.001) and EVI1 expression (P=0.007) were significantly associated with the risk of death. Multivariate Cox regression analysis confirmed that EVI1 expression (P = 0.017) was an independent prognostic indicator for OS in HCCA, as was TNM stage (P = 0.013, Table 2).

**EVI1 promotes HCCA cell proliferation in vitro**

To investigate the biological functions of EVI1 in HCCA, the expression of EVI1 was detected in 4 CCA cell lines and one HIBEpiC line by qRT-PCR and Western blotting. As shown in Figure 2A, the expression of EVI1 was highest in QBC939 cells and
was significantly lower in FRH0201 cells. Then, QBC939 cells and FRH0201 cells were used for further functional studies. We constructed a stable EVI1-knockdown cell line (QBC939 cells) by transfection of lentiviral particles carrying an EVI1-specific shRNA. The mRNA level of EVI1 was remarkably decreased in the shEVI1 group compared with the control (Ctrl) and NC groups (P=0.0052, Figure 2B). This downregulation of EVI1 expression at the protein level was confirmed by Western blotting (Figure 2B). A CCK-8 assay showed that knocking down EVI1 expression resulted in significantly suppressed cell proliferation in the shEVI1 group compared with that in the Ctrl and NC groups, (Figure 2D). Similar results were observed in a colony formation assay and an EdU assay (Figure 2F and H). To further explore the function of EVI1 in tumour proliferation, we transfected FRH0201 cells with an EVI1-overexpression plasmid. The overexpression efficiency was detected by qRT-PCR and Western blotting (Figure 2C). The results showed that EVI1 overexpression promoted cell proliferation (Figure 2E, G and I). Therefore, these results demonstrate that EVI1 may play an important role in HCCA cell proliferation.

Figure 1. Expression level of EVI1 in HCCA tissue samples and the relationship between EVI1 and overall survival. (A) EVI1 expression in 30 pairs of HCCA tissue and adjacent normal bile duct tissue. (B) Protein expression of EVI1 in HCCA tissue samples detected by Western blotting. (C) Representative immunohistochemical staining for EVI1 in 114 HCC samples. (D) Kaplan-Meier survival analysis of patients with HCCA stratified by EVI1 expression. Overexpression of EVI1 was associated with decreased overall survival in the patients with HCCA. Data are presented as the mean±SEM and were analysed with a paired-sample t test. **P<0.01, N=normal, T=tumour.
Figure 2. EVII promotes the growth of HCCA cells. (A) Quantitative real-time PCR (qRT-PCR) and Western blot analyses of EVII expression in CCA cell lines and human intrahepatic biliary epithelial cells (HIBEpiC). (B) Knocked down EVII expression in QBC939 cells detected by qRT-PCR and Western blotting. (C) FRH0201 cells transduced with an EVII-overexpression plasmid. The overexpression efficiency was detected by qRT-PCR and Western blotting. (D, F and H) CCK-8 assays, colony formation assays and EdU assays to detect the proliferation of QBC939 cells following shRNA transfection. (E, G and I) FRH0201 cell proliferation analysed by CCK-8, colony formation and EdU assays following transfection with the EVII-overexpression plasmid. Data are presented as the mean±SEM.

**P<0.01, ***P<0.001, Ctrl=without transfection, NC=transfected with a noncoding shRNA, shEVI1= transfected with an EVII-specific shRNA, and EVI1= transfected with the EVII-over-expression plasmid.

Knocking down EVII expression blocks cell cycle progression and promotes apoptosis

To investigate the mechanism underlying the suppression of cell proliferation observed after silencing EVII, we assessed the effects of knocking down EVII expression on the cell cycle and apoptosis by flow cytometry. As shown in Figure 3A, the percentage of S-phase cells was obviously higher in the shEVI1 group than in the Ctrl and NC groups (S%: 45.77% vs. 33.33% or 33.93%, respectively, P =0.000), implying that knocking down EVII expression might cause S-phase arrest in QBC939 cells. To further characterize the observed S-phase arrest, we examined the levels of several known S-phase cell cycle regulatory factors. Western blot analysis demonstrated that shEVI1 significantly increased p21 protein levels and decreased CDK2 and Cyclin A protein levels in QBC939 cells. The percentage of apoptotic cells in the shEVI1 group was notably increased, as determined by using Annexin V-PE staining for flow cytometry analysis (Figure 3C,
shEV1: 12.04%, Ctrl: 1.94%, and NC: 2.06%). TUNEL assays produced the same results (Figure 3D). Subsequently, we detected changes in apoptosis-related proteins by Western blotting. Knocking down EVII expression decreased the expression of Bcl-2 and increased the expression of Bax and cleaved caspase-3 (Figure 3E). Collectively, these results indicated that the downregulation of EVII expression markedly affected the cell cycle and boosted apoptosis.

Knocking down EVII expression promotes the expression of PTEN and represses the phosphorylation of AKT

We assessed the effect of knocking down EVII expression on PTEN protein expression in vivo and in vitro. As shown in Figure 4D and Figure 5E, the expression of PTEN was significantly increased by knocking down EVII expression. Since AKT is an important target of PTEN and PTEN negatively regulates the phosphorylation of AKT[17], the expression of phosphorylated AKT was also examined. Western blot analysis indicated that AKT phosphorylation was significantly reduced by knocking down EVII expression in vivo and in vitro (Figure 4D and Figure 5E). In PTEN-depleted cells, the inhibitory effect of EVII on pAKT was attenuated (Figure 4E). These results indicated that EVII could regulate the AKT signalling pathway by regulating PTEN in HCCA. These results suggest that downregulation of PTEN expression by EVII may contribute to EVII-induced tumour carcinogenesis and development.

Knocking down EVII expression significantly inhibits tumour growth in vivo

To further investigate the biological effects of EVII on HCCA tumourigenesis in vivo, we subcutaneously injected cells (shEVII- or NC-transfected cells) into nude mice and monitored tumour growth. As shown in Figure 5A, compared with NC transfection, shEVII transfection significantly inhibited tumour growth. In addition, the average tumour weight was remarkably lower in the shEVII group than in the NC group (P<0.01, Figure 5C). Furthermore, the expression of PTEN in the shEVII group was higher than that in the NC group, as determined by qRT-PCR and Western blotting (Figure 5D and E). The expression of pAKT was also decreased in the shEVII group compared with the NC group (Figure 5E). These results were consistent with the results obtained in vitro. These results further confirm that downregulation of EVII expression suppresses the development of HCCA.

PTEN expression inversely correlates with EVII expression in HCCA

To analyse the mechanism by which EVII promotes the progression of HCCA, we evaluated EVII and PTEN expression in an HCCA TMA. We found that low expression of PTEN mainly occurred in the tumour tissue samples with high EVII expression, and high expression of PTEN mainly occurred in the tumour tissue samples with low EVII expression (Figure 4A). A statistically significant inverse correlation was observed between the EVII and PTEN proteins (r=-0.3122, P=0.0007, Figure 4B). This result was also verified by qRT-PCR analysis of fresh tumour tissue samples (r=-0.3687, P=0.045, Figure 4C).

Table 1: Correlations between EVII expression and clinicopathological characteristics of HCCA patients

| Characteristic                  | Case(n) | EVII expression | χ² value | P-value |
|--------------------------------|---------|----------------|----------|---------|
|                                |         | High (n) | Low (n) |          |         |
| Age (years)                    |         |          |          |          |         |
| ≤60                            | 37      | 18       | 19       | 0.109   | 0.741   |
| >60                            | 77      | 40       | 37       |          |         |
| Gender                         |         |          |          |          |         |
| Male                           | 81      | 38       | 43       | 1.759   | 0.185   |
| Female                         | 33      | 20       | 13       |          |         |
| Histological grade            |         |          |          |          |         |
| Well                           | 30      | 9        | 21       | 7.100   | 0.008   |
| Moderately/Poorly             | 84      | 49       | 35       |          |         |
| Tumor size (cm)                |         |          |          |          |         |
| >2.5                           | 53      | 33       | 20       | 5.139   | 0.023   |
| ≤2.5                           | 61      | 25       | 36       |          |         |
| Tumor depth                    |         |          |          |          |         |
| T1                             | 40      | 21       | 19       | 0.065   | 0.799   |
| T2-T4                          | 74      | 37       | 37       |          |         |
| Lymphatic metastasis          |         |          |          |          |         |
| Absent                         | 75      | 39       | 36       | 0.111   | 0.739   |
| Present                        | 39      | 19       | 20       |          |         |
| TNM stage                      |         |          |          |          |         |
| I/II                           | 73      | 40       | 33       | 1.246   | 0.264   |
| III/IV                         | 41      | 18       | 23       |          |         |

Table 2: Univariate and multivariate analyses of prognostic factors for overall survival in HCCA patients

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR      | 95%CI     | P-value | HR      | 95%CI     | P-value |
| Age(≥60 vs ≤60)            | 0.576   | 0.314-1.058 | 0.075  |         |         |         |
| Gender(Male vs Female)     | 1.108   | 0.624-1.969 | 0.726  |         |         |         |
| Histological grade         | 2.214   | 1.040-4.712 | 0.039  |         |         |         |
| (Well vs Moderately/Poorly)|         |          |         | 0.720   | 0.328-1.580 | 0.413   |
| Tumor size(>2.5 vs ≤2.5)   | 0.442   | 0.252-0.776 | 0.004  | 1.749   | 0.980-3.119 | 0.058   |
| Tumor depth(T1 vs T2-T4)   | 1.289   | 0.694-2.394 | 0.421  |         |         |         |
| Lymphatic metastasis       | 2.035   | 1.180-3.511 | 0.011  | 1.681   | 0.567-4.986 | 0.349   |
| (Absent vs Present)        |         |          |         | 0.254   | 0.083-0.780 | 0.017   |
| TNM stage(I/II vs III/IV)   | 2.437   | 1.412-4.206 | 0.001  |         |         |         |
| EVII expression            | 2.269   | 1.255-4.102 | 0.007  | 0.451   | 0.240-0.846 | 0.013   |
| (High vs Low)              |         |          |         |         |         |         |

HR, hazard ratio; 95% CI, 95% confidence interval.

PTEN expression inversely correlates with EVII expression in HCCA

To analyse the mechanism by which EVII promotes the progression of HCCA, we evaluated EVII and PTEN expression in an HCCA TMA. We found that low expression of PTEN mainly occurred in the tumour tissue samples with high EVII expression, and high expression of PTEN mainly occurred in the tumour tissue samples with low EVII expression (Figure 4A). A statistically significant inverse correlation was observed between the EVII and PTEN proteins (r=-0.3122, P=0.0007, Figure 4B). This result was also verified by qRT-PCR analysis of fresh tumour tissue samples (r=-0.3687, P=0.045, Figure 4C).
Figure 3. Knocking down EVI1 expression affects cell cycle progression and apoptosis regulation in QBC939 cells. EVI1 suppresses the protein expression of PTEN and thus modulates the PI3K/AKT pathway. (A) Flow cytometry analysis of the cell cycle was performed to determine the cell cycle distribution after transfection. (B) Western blot analysis of p21, CDK2 and Cyclin A expression in transfected QBC939 cells was performed. (C) Flow cytometry analysis of apoptosis was performed to evaluate cell apoptosis after transfection. (D) A TUNEL assay was carried out to assess apoptosis. (E) BCL2, Bax and Caspase 3 expression was measured by Western blotting. Data are presented as the mean±SEM. **P<0.001, Ctrl=without transfection, NC= transfected with a noncoding shRNA, shEVI1= transfected with an EVI1-specific shRNA.
Figure 4. PTEN expression is inversely correlated with EVI1 expression in human HCCA tissue. (A) PTEN expression was low in EVI1-positive tissue samples and high in EVI1-negative tissue samples. (B) The correlation between EVI1 and PTEN expression in TMA clinical samples was determined. (C) The correlation between relative EVI1 mRNA expression (the data in Figure 1A) and relative PTEN mRNA expression was determined in 30 pairs of HCCA tissue and adjacent normal bile duct tissue. (D) Comparisons of PTEN and AKT signalling pathways were analysed by Western blotting. (E) QBC939 cells transfected with NC or shEVI1 were treated with siPTEN. After 48 h of treatment, cell lysates were harvested for Western blotting. Western blot analysis showed that the repression of pAKT expression mediated by shEVI1 could be partially rescued by siPTEN. Ctrl=without transfection, NC= transfected with a noncoding shRNA, shEVI1= transfected with an EVI1-specific shRNA, siPTEN= transfected with a PTEN-specific siRNA.

Discussion

Due to the latent genesis and development of HCCA, it is difficult to diagnose and treat this disease in the early phase. There are no effective treatments for advanced HCCA. Therefore, the prognosis of advanced-stage patients is very poor\cite{6, 18, 19}. EVI1 has been confirmed to participate in solid tumour genesis and development\cite{20}. When inappropriately expressed, EVI1 is considered an independent poor
In particular, a recent study found that EVI1 was overexpressed and associated with a poor prognosis in ICC\(^\text{[13]}\). However, the status of EVI1 expression in HCCA is still unknown.

In the present research, we focused on the expression levels of EVI1 and its biological function in HCCA. Our study showed that EVI1 was overexpressed in HCCA tissue compared with adjacent normal bile duct tissue. Furthermore, we investigated the relationships between EVI1 expression and clinicopathological characteristics in HCCA. We found that high EVI1 expression was correlated with a low histological grade and large tumours and predicted poor OS. Multivariate analysis showed that EVI1 was an independent prognostic factor in HCCA patients.

Similar results have also been...
reported in ICC\[13\], hepatocellular carcinoma[24], colorectal cancer[25], prostate cancer[26], lung cancer[27], glioblastoma multiforme[28] and so on[29, 30]. These data indicate that EVI1 plays an important role in tumour progression.

Queisser et al. reported that downregulation of EVI1 expression suppressed cell growth and induced cell cycle arrest and apoptosis in prostate cancer[26]. Wang et al. found that EVI1 silencing reduced cell proliferation and apoptosis resistance in breast carcinoma[31]. In pancreatic cancer cells, EVI1 depletion remarkably inhibits cell growth and migration, indicating its oncogenic roles[32]. To explore the biological function of EVI1 in HCCA cells, we constructed a stable EVI1-knockdown cell line with lentiviral particles. We demonstrated that knocking down EVI1 expression inhibited HCCA cell proliferation both in vitro and in vivo. Furthermore, overexpression of EVI1 could promote tumour cell growth in vitro. Downregulated EVI1 expression blocked the cell cycle in S phase and promoted cell apoptosis. All of these results were consistent with those of the aforementioned studies.

Cell proliferation and apoptosis are regulated by multiple signalling pathways. The effects of the PI3K/AKT signalling pathway on cell proliferation and apoptosis have been proven in many kinds of cancers, including HCCA[33-36]. PTEN negatively regulates the PI3K/Akt pathway in cancer, exerting tumour suppressor activity[17, 37, 38]. PTEN has been reported to be a direct target of EVI1 and related to EVI1-mediated biological effects on cell proliferation and survival in human leukaemia cells[34]. In this study, we found a significant negative correlation between EVI1 and PTEN expression in tumour tissue samples. Therefore, we speculated that PTEN was an important target of EVI1 in HCCA. Further study showed that knocking down EVI1 expression increased the protein level of PTEN and reduced the phosphorylation of AKT in QBC939 cells. Moreover, downregulation of PTEN expression could attenuate the influence of EVI1 on the AKT pathway. These results indicated that EVI1, as a transcription factor, performed its oncogenic roles at least partially by repressing PTEN expression and activating AKT signalling pathways.

In conclusion, we demonstrated that EVI1 was overexpressed in HCCA tissue samples and cell lines and that its expression was negatively correlated with HCCA patient prognosis. In addition, our study suggested that EVI1 might regulate tumour cell proliferation by repressing PTEN and activating the AKT pathway. Therefore, EVI1 may be a potential target in HCCA treatment.

Acknowledgements

This study was funded by Key Technological Research Projects of Shandong Province (26010104011824).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Current gastroenterology reports. 2017; 19: 2.
2. LaFemina J, Jarnagin WR. Surgical management of proximal bile duct cancers. Langenbeck's archives of surgery. 2012; 397: 869-75.
3. Li H, Zhang ZY, Zhou ZQ, Guan J, Tong DN, Zhou GW. Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. Oncotarget. 2016; 7: 28888-97.
4. Bird NT, McKenna A, Dodd J, P斯顿 G, Jones R, Malik H. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. The British journal of surgery. 2018; 105: 1408-16.
5. Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T. Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. ANNI SURG ONCOL/3655. 2008; 15: 590-9.
6. Yang WL, Zhang XC, Zhang DW, Tong BF. Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma. Hepatobiliary & pancreatic diseases international : HBPD INT. 2007; 6: 631-5.
7. Mahipal A, Kommalapati A, Tella SH, Lim A, Kim R. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Investig Drugs. 2018; 27: 709-20.
8. Goyama S, Kurokawa M. Evi-1 as a critical regulator of leukemic cells. International journal of hematology. 2010; 91: 753-7.
9. Nolte F, Hofmann WK. Molecular mechanisms involved in the progression of myeloproliferative syndromes. Front oncology. 2010; 6: 445-55.
10. Lugbhart S, Figueuza ME, Bindels E, Skrabak L, Valk PJ, Li Y, et al. Aberrant DNA hypermethylation signature in acute myeloid leukaemia directed by EVII. Blood. 2011; 117: 234-41.
11. Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang JM, et al. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer. 1996; 74: 1518-25.
12. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A. Evaluation of EVI1 and EVIIs (Delta324) as potential therapeutic targets in ovarian cancer. Gynecologic oncology. 2010; 118: 189-95.
13. Tanaka M, Shibahara J, Ishikawa S, Ushiku T, Morikawa T, Shinozaki-Ushiku A, et al. EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma. Virchows Arch. 2019; 474(1): 39-46.
14. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshih I, Nannya Y, Nitta E, et al. EVI1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood. 2011; 117: 3637-28.
15. Eng C. PTEN: one gene, many syndromes. Human mutation. 2003; 22: 183-98.
16. Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer research. 1986; 46: 4109-15.
17. Stambolis V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. EVI1 splice variants modulate functional responses in ovarian cancer cells. Molecular oncology. 2013; 7: 647-68.
18. Shi XD, Yu XH, Wu WR, Xu XL, Wang JY, Xu LB, et al. Dickkopf-1 expression is associated with tumorigenicity and lymphatic metastasis in human hilar cholangiocarcinoma. Oncotarget. 2016; 7: 70378-87.
19. Chamberlain RS, Blumgart LH. Hilar cholangiocarcinoma: a review and commentary. ANNI SURG ONCOL/3655. 2000; 7: 55-66.
20. Dutta P, Bui T, Bauckman KA, Keyomarsi K, Mills GB, Nanjundan M. EVI1 splice variants mediate functional responses in ovarian cancer cells. Molecular oncology. 2013; 7: 647-68.
21. Glass C, Wilson M, Gonzalez R, Zhang Y, Perkins AS. The role of EVI1 in myeloid malignancies. Blood cells, molecules & diseases. 2014; 53: 67-76.
22. Matsumo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, et al. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. Haematologica. 2014; 99:e225-7.
23. Qin Y-Z, Zhao T, Zhu HJ, Wang J, Jia JS, Bai Y-J, et al. High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. Medical Science Monitor. 2018; 24: 756-67.
24. Yu MC, Lee CW, Lee YS, Lian JH, Tsai CL, Liu YP, et al. Prediction of early-stage hepatocellular carcinoma using Oncoscan chromosomal copy number aberration data. World journal of gastroenterology. 2017; 23: 7818-29.
25. Makondi PT, Chu CM, Wei PL, Chang YJ. Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer. PloS one. 2017; 12: e0180616.

26. Queisser A, Hagedorn S, Wang H, Schaefer T, Konantz M, Alavi S, et al. Ecotropic viral integration site 1, a novel oncogene in prostate cancer. Oncogene. 2017; 36: 1573-84.

27. Xu X, Liu S, Ji X. Overexpression of ecotropic viral integration site-1 is a prognostic factor of lung squamous cell cancer. OncoTargets and therapy. 2017; 10: 2739-44.

28. Hou A, Zhao L, Zhao F, Wang W, Niu J, Li B, et al. Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme. OncoTargets and therapy. 2016; 9: 315-20.

29. Bard-Chapeau EA. Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. PNAS. 2012; 109:2168-73.

30. Lang WJ, Chen FY. The reciprocal link between EVI1 and miRNAs in human malignancies. Gene. 2018; 672: 56-63.

31. Wang H, Schaefer T, Konantz M, Braun M, Varga Z, Paczuulla AM, et al. Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. Cancer research. 2017; 77: 2148-60.

32. Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, et al. EVII oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene. 2014; 33: 2454-63.

33. Spangle JM, Roberts TM, Zhao JJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochimica et biophysica acta Reviews on cancer. 2017; 1868: 123-31.

34. Nasser MI, Masood M, Wei W, Li X, Zhou Y, Liu B, et al. Cordycepin induces apoptosis in SGC7901 cells through mitochondrial extrinsic phosphorylation of PI3K/Akt by generating ROS. INT J ONCOL. 2017; 50: 911-9.

35. Sang H, Li T, Li H, Liu J. Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma. PloS one. 2013; 8: e81347.

36. Leelawat K, Udomchaiprasertkul W, Narong S, Leelawat S. Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells. J Cancer Res Clin Oncol. 2010; 136: 1537-44.

37. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nature reviews Molecular cell biology. 2012; 13: 283-96.

38. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999; 96: 6199-204.